Taken together, KRASG12C inhibitor-targeted immunotherapy or cotreatment of KRASG12C inhibitor with immunotherapy represents new directions in tackling drug resistance to KRASG12C inhibitors through remodeling the immunosuppressive tumor microenvironment driven by KRAS mutants. Here, KRAS is linked to neoplasm.